BRMTISH MEDICAL JOURNAL VOLUME 293 22 NOVEMBER 198622 NOVEMBER 1337 poor, nausea and vomiting were reduced by increasing the dose of the maintenance infusion during subsequent treatment to 5 and 6 mg/kg, respectively. This shows that the antiemetic effect of the drug can be optimised individually. Neither regimen produced excessive side effects. Interestingly, diarrhoea was considerably reduced in the group receiving the continuous infusion, and it may be that wide fluctuations in plasma metoclopramide concentrations result in excessive intestinal hurry with resultant diarrhoea. Extrapyramidal reactions to metoclopramide are rare in this age group.
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Neither regimen produced excessive side effects. Interestingly, diarrhoea was considerably reduced in the group receiving the continuous infusion, and it may be that wide fluctuations in plasma metoclopramide concentrations result in excessive intestinal hurry with resultant diarrhoea. Extrapyramidal reactions to metoclopramide are rare in this age group.
In view of an increasing tendency towards combination antiemetic treatment for emesis induced by cytotoxic drugs and the attendant concern over potential drug interactions the optimal use of individual antiemetics is considerably important. Thus we are encouraged by the considerable improvement in antiemetic effect achieved by high dose metoclopramide given as a loading dose and maintenance infusion after the application of simple pharmacokinetic principles. Future studies need to address the problems of the route and technique of administration of antiemetics and the dosage as well as identifying new compounds and combinations. Kris et al documented the time course of nausea and vomiting after administration of cisplatin.2 They showed that nausea persisted for five days in 400% of patients and vomiting in 200%, with a peak incidence at three days after administration. In our study there was no difference in the duration of nausea and vomiting between the two arms, but the peak incidence of delayed nausea at three days agrees with the sttudy of Kris et al. ' This suggests that control of acute emesis after cisplatin does not necessarily reduce subsequent delayed emesis, and thus further improvements are required.
We thank the pharmacy department and the nursing staff in the department of clinical oncology for their help in this study. We also thank Miss M E Kerr for statistical help. 
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Introduction
Oestrogen replacement in postmenopausal women reduces both symptoms of the climacteric and excess bone resorption in a dose dependent manner.'2 During the menstrual cycle, however, though the changes that occur in the plasma oestrogen concentration are of the same order of magnitude as those in women receiving postmenopausal hormone replacement therapy, they are not accompanied by any change in either oestrogen dependent symptoms or bone turnover.3 A possible explanation for this difference is that the response to oestrogen is near maximal at the plasma concentration present -during menstruation and that only small changes in response occur with oestrogen concentrations within and above the premenopausal range. If the response in bone to oestrogen has this relation it has implications for postmenopausal hormone replacement treatment, since the adverse effects of oestrogen treatment are dose related.' 4 Moreover, high doses ofoestrogen have unwanted effects on bone as a result ofinhibition ofbone formation, which would be avoided by using the minimal dose of oestrogen to suppress resorption.
The establishment of such a dose has thus far been difficult because oestrogens are usually given by mouth. This causes hepatic "first pass" metabolism of the oestrogen, which appears in plasma as various metabolites with variable biological activity' and increased concentrations of sex hormone binding globulin, which reduces the free hormone.6 Taken together these two phenomena make it impossible to assign any meaningful biological value to measured oestrogen concentrations after oral administration. Transdermal oestrogen, however, avoids both of these effects57 and the plasma oestradiol concentration is then an accurate indicator of biological activity.
Recently a means has been devised to administer drugs transdermally at a fixed rate by using a skin patch incorporating a rate limiting membrane.' We have used this method of delivery to study the response of symptoms, gonadotrophin release, and bone resorption to varying concentrations of plasma oestrogen in postmenopausal women.
Patients and methods
We studied 26 normal postmenopausal women attending our clinic because of symptoms of the climacteric. All were postmenopausal as defined by at least six months' amenorrhoea together with raised plasma follicle stimulating hormone and low plasma oestradiol concentrations. No patient had received any hormone replacement therapy in the month before the study and none was receiving any drug known to affect calcium or bone metabolism. All patients received treatment with transdermal oestradiol from an adhesive patch with a controlled rate of release (TTS Estraderm; Ciba-Geigy, Horsham, Sussex). Patients were randomly allocated to receive one of three different sized patches delivering oestradiol at a rate of 0-025 mg, 0-05 mg, or 0 1 mg daily. The table gives the details of patients within each group.
All patients were studied basally and after three weeks of treatment. On each occasion a clinical assessment was made to enable a symptom score to be derived and blood and urine were obtained after an overnight fast for estimation of plasma follicle stimulating hormone and oestradiol concentrations and urinary excretion of calcium, creatinine, and hydroxyproline. Urinary calcium and creatinine were measured by standard autoanalyser techniques. Urinary hydroxyproline was measured by an automated colorimetric procedure after resin catalysed hydrolysis.8 Follicle stimulating hormone and oestradiol concentrations were measured by specific radioimmunoassays.
Statistical analysis within each treatment group was by paired t tests where the data were normally distributed and the Wilcoxon signed rank test otherwise.
Results
Treatment with the three doses of oestradiol resulted in a progressive rise in the mean plasma oestradiol concentration at three weeks. This rose from 36 (SE 4) pmol/l (9-7 (1-1) pg/ml) to 79 (18) pmol/l (21-3 (4-9) pg/ml) (p<0-05) with 0-025 mg/day; from 46 (16) pmol/l (12-4 (4-3) pg/ml) to 122 (27) pmol/l (32-9 (7-3) pg/ml) (p<0-01) with 0-05 mg/day; and from 41 (6) pmol/l (11-1 (1-6) pg/ml) to 281 (31) pmol/l (75-9 (8-4) pg/ml) (p<0001) with 0-1 mg/day (table).
All doses of oestrogen led to some relief of symptoms, but this was more pronounced with the two highest doses (table) .
Plasma follicle stimulating hormone concentrations fell with all doses of oestrogen: from 62-5 (SE 3-6) mU/ml to 51-7 (4-8) mU/mr (p<0-01) with 0-025 mg daily; from 53-6 (7-7) mU/mI to 38-6 (5-7) mU/mI (not significant) with 0-05 mg daily; and from 58-6 (3-7) mU/ml to 34-3 (5-2) mU/mI (p<0-001) with 0-1 mg daily (table) .
Treatment with 0-025 mg oestradiol daily caused a fall in urinary calcium excretion from 0-24 (SE 0-04) (molar ratio to creatinine) to 0-18 (0104), but this failed to reach statistical significance. The higher doses produced significant changes: from 0-28 (0-07) to 0-18 (0-06) (p<0-01) with 0-05 mg daily, and from 0-28 (0-05) to 0-15 (0-02) (p<0-05) with 0-1 mg daily. Similar changes also occurred in urinary hydroxyproline excretion, which rose non-significantly with 0-025 mg daily but fell from 0-014 (SE 0-003) (molar ratio to creatinine) to 0-012 (01002) (not significant) with 0-05 mg daily and from 0-014 (01002) to 0-010 (01001) (p<005) with 0-1 mg daily (table). Relation between climacteric symptoms, plasma follicle stimulating hormone concentration, hydroxyproline:creatinine ratio, and calcium:creatinine ratio in urine collected after overnight fast and plasma oestradiol concentration in postmenopausal women treated with transdermal oestradiol. Data expressed as means and SE; untreated data combined for the three groups. In each case curved line is arbitrary line illustrating change in that variable with plasma oestrogen concentration. Conversion: SI to traditional units-Oestradiol: 1 pmol/l-0-27 pg/ml.
Since there were no significant differences in untreated values of symptom score, follicle stimulating hormone concentration, and urinary calcium and hydroxyproline excretion among the three treatment groups the untreated data were combined, allowing each of the measured variables to be related to the ambient plasma oestradiol concentration as a set of dose response curves. The figure shows the result.
Discussion
This study confirms the dose dependent action of oestrogen in reducing climacteric symptoms, gonadotrophin secretion, and bone resorption in the postmenopausal state.'2 Because transdermal oestradiol does not undergo "first pass" hepatic metabolism and does not alter plasma binding proteins like oral oestradiol it is possible to relate the biological responses to the measured plasma concentrations of oestradiol achieved during treatment (figure). Despite the symptom study being uncontrolled the four responses were dose dependent, the greatest response occurring in the postmenopausal range of oestradiol but becoming asymptotic above a plasma oestradiol concentration of 150 pmol/l (41 pg/ml). This agrees with the observation that the changes in plasma oestradiol concentrations during the menstrual cycle, which are all above 150 pmol/l, have no measurable effect on bone turnover. 3 Other workers have noted that the dose oforal oestrogen required to achieve each of its actions is different. I response curves for climacteric symptoms, gonadotrophin release from the pituitary, and bone resorption are all congruent. This equivalence adds weight to our previous studies which suggested that the action of oestrogen on bone is a difect receptor mediated response similar to that underlying the reduction in follicle stimulating hormone and not an indirect action via altered concentration of the calcitropic hormones, which might be expected to produce different dose response characteristics.90 ' It is clear from these results that there is little to be gained from using doses of oestrogen above that which gives an effect equivalent to that produced by a plasma oestradiol concentration of 1-50 pmolIl (41 pg/ml). Indeed, any substantial increase in dose above this level is likely to increase adverse reactions without clinical benefit. Anmong these is the excessive suppression of bone rembdelling,' which is probably essential for the maintenance of healthy bone.
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Hepatoceliular carcinoma in urban born blacks: frequency and relation to hepatitis B virus infection M C KEW, C KASSIANIDES, J HODKINSON, A COPPIN, A C PATERSON Abstract Chronic hepatitis B virus infection is far less common in urban born than in rural born southern African,blacks, who also have a high incidence-ofhepatocellular carcinoma. A case-control study was carried out to determine the relative frequency of hepatocellular carcinoma and its relation to hepatitis B virus infection in urban born blacks. Three hundred and ninety two black patients with hepatocellular carcinoma and matched controls seen at two city hospitals were classified by questioning as urban born or rural born. The ratio of rural born to urban born blacks among the controls was 1-1:1-0 (207/185), whereas in the patients with cancer the ratio was 4-8:1-0(324/68) (p<O0001). Analysis of the prevalence of hepatitis B markers in 62 urban born and matched rural born blacks with hepatoceliular carcinoma showed no diffetences in the frequency of current-or past hepatitis B virus infection.
It is concluded that urban born blacks are less likely than rural born blacks to develop hepatoceilular carcinoma, but when they 
